A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

Part of paid clinical trials in Dallas, Texas.

Sponsor
Eli Lilly and Company
Study ID
NCT06890611
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 64 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up.

Key Dates

Start date
Mar 25, 2025
Status verified
Oct 2025
Primary completion
Sep 26, 2025
Completion
Sep 26, 2025

Study Design

Enrollment
125 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Bimagrumab Dose 1 Reference Material
    Participants will receive a single dose of bimagrumab subcutaneously (SC)
  • Experimental: Bimagrumab Dose 1 Test Material + Tirzepatide (Coadministration)
    Participants will receive a single dose of bimagrumab SC and a single dose of tirzepatide SC
  • Experimental: Bimagrumab Dose 1 Test Material + Tirzepatide (Coformulation)
    Participants will receive a single dose of bimagrumab with tirzepatide SC
  • Experimental: Bimagrumab Dose 2 Test Material + Tirzepatide (Coadministration)
    Participants will receive bimagrumab SC and tirzepatide SC for 4 weeks
  • Experimental: Bimagrumab Dose 2 Test Material + Tirzepatide (Coformulation)
    Participants will receive bimagrumab with tirzepatide SC for 4 weeks

Primary Outcome Measure

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Bimagrumab Test Material [ Time Frame: Predose through Week 13 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research UnitDallasTexas75247-

Find similar trials in Dallas, TX

By research site
Fortrea Clinical Research Unit· Dallas, TX

Related Studies